Katul (Drospirenone, Ethinylestradiol)

The drospirenone component acts as a progestogen with anti‑mineralocorticoid activity, while ethinylestradiol is a synthetic estrogen. Together they bind to progesterone and estrogen receptors, suppress the hypothalamic‑pituitary‑ovarian axis, prevent the LH surge, and thus block ovulation. They also thicken cervical mucus and alter the endometrium to reduce fertilization and implantation.

The dosing regimen for Katul is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, following the specific pack instructions provided by the prescriber. Patients should not alter the dose or frequency without medical guidance.

Katul is contraindicated during pregnancy; it must be discontinued if pregnancy is confirmed. For breastfeeding women, combined oral contraceptives are generally not recommended during the early postpartum period because estrogen may affect milk production. Consultation with a healthcare provider is essential to choose an appropriate contraceptive method.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, then replies with pricing, availability, shipping details, and any necessary import documentation.

Katul contains drospirenone, which has anti‑mineralocorticoid properties that may reduce water retention compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ, with a potentially lower incidence of weight gain but a similar risk of thromboembolic events. Choice depends on individual risk factors and physician assessment.

Katul tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Katul is taken orally, usually as one tablet each day, at the same time each day, without regard to meals. The typical pack contains a series of active tablets followed by placebo tablets to maintain a regular dosing schedule, but patients should follow the specific instructions given by their prescriber.

The most serious risks include venous thromboembolism, stroke, and myocardial infarction, particularly in women with pre‑existing risk factors such as smoking, hypertension, or a history of clotting disorders. Severe allergic reactions and liver dysfunction are also rare but critical concerns. Prompt medical attention is required if symptoms such as sudden chest pain, severe headache, or jaundice occur.

Katul should not be used by women who are pregnant, have a known history of thromboembolic disease, estrogen‑dependent tumors, uncontrolled hypertension, or severe liver disease. It is also contraindicated in smokers over 35 years of age and in individuals with known hypersensitivity to drospirenone, ethinylestradiol, or any tablet excipients. A healthcare professional must evaluate suitability before prescribing.